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A novel beta-coronavirus was reported in Wuhan, Hubei Province, China, 
which in December 2019, which was named SARS-CoV-2. It causes 
Coronavirus Disease 2019 (COVID-19) that can affect lung tissue and 
airways. The immune system can respond to SARS-CoV-2 infection via 
various mechanisms. Cytokines play crucial roles in COVID-19. In the 
present study, the latest information on the immune responses, transmission, 
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Recently, a novel beta-coronavirus has been reported 
in Wuhan which is called SARS-CoV-2. SARS-CoV2 
causes COVID-19, a disease that affects the lung tissue 
and airways (1). Since this virus has been spread 
rapidly in many countries, it is deduced that SARS-
CoV-2 can be a threat to global public health (2), 
COVID-19 was declared a worldwide pandemic by the 
World Health Organization (WHO) on 11 March 2020 
(3). Until 5th July 2020, more than 200 countries 
reported cases of COVID-19. There were 10922324 
people diagnosed with COVID-19 worldwide and the 
death toll was announced at 523011 (4). 
 
Immune Responses 
The immune system is made up of two arms: the innate 
immune system and the adaptive immune system. The 
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innate immune system initiates immune responses by 
the recognition of pathogens and the induction of pro-
inflammatory cytokines and chemokines. Pattern 
recognition receptors (PRRs) are responsible for the 
detection of microbes in the innate immune system 
(5,6). Major sensors of RNA viruses such as Retinoic 
acid-inducible gene I and Melanoma 
DifferentiationAssociated Protein 5 cause the 
activation of nuclear factor-κB (NF-κB) and IFN 
regulatory factor 3 (IRF3) cascades, which ultimately 
leads to an increase in IFN-I (7). 
It has been suggested that both the innate and 
adaptive responses play a significant role in SARS-
CoV-2 outcomes. Besides, evidence suggests that T 
cells responses are essential to the effectiveness of the 
immune system against severe acute respiratory 
syndrome (SARS) and the Middle East respiratory 
syndrome (MERS) infections. Such immunity 
responses are probably similar to those against 
COVID-19. Nonetheless, T lymphocyte helper 1 (Th1) 
and TCD8+ cells mediate the main protection against 
SARS-CoV-2 (8). 
Furthermore, B-cell responses also play a 
fundamental role in the immune response to SARS-
CoV-2 by the production of virus-neutralizing 
antibodies. Given the effectiveness of TCD8+ cells in 
most cases, TCD8+ may lead to lung tissue damages. 
It has been reported that the level of cytokines and 
chemokines such as IL2, IL7, IL10, GSCF, IP10, 
MCP1, MIP1A, and TNFα increase in ICU patients 
with SARS-CoV-2 infection compared to non-ICU 
patients with COVID-19 (8,9). Besides, it reported 
increased levels of anti-inflammatory cytokines such 
as IL-4 and IL10 in a patient with COVID-19 (9,10). 
Although IL-4 shows a decrease in SARS-CoV 
infection, (11) however it increases in SARS-CoV-2 
infection (10). Thus, there is a significant difference 
between cytokine profiles in SARS-CoV infection and 
SARS-CoV-2 infection. It is noteworthy that 
coronaviruses use numerous strategies to evade the 
immune system. Previous studies have shown that 
SARS-CoV, MERS-CoV, and SARS-CoV-2 can 




Our knowledge about SARS-CoV-2 is still limited, 
however, direct transmission of COVID-19 has been 
confirmed. Thus, it can spread from person to person 
via viral particles in naturally produced droplets from 
sneezes or coughs. Also, SARS-CoV-2 transmission 
can occur through oral, nasal, eye mucous membranes 
contact, and through the aerosols (12). Coronaviruses 
can survive on surfaces such as glass, metal, and plastic 
for up to 9 days, and can be inactivated with lipid 
solvents containing 70% ethanol and 0.1% sodium 
hypochlorite (13). 
 
Symptoms of COVID-19 
The main symptoms of COVID-19 include malaise, 
cough, fever, shortness of breath, headache, diarrhea, 
and sore throat (14). Recently, researchers found that 
the average incubation period of the COVID-19 is 
approximately 5 days, however, it may take up to 14 
days (15, 16). Other complications of the COVID-19 
include acute respiratory distress syndrome (ARDS), 
acute heart damage, secondary infections, abnormal 




SARS-CoV-2 is spreading rapidly all over the world. 
Both arms of the immune system mediate immune 
responses to SARS-CoV-2. The main route of SARS-
CoV-2 transmission is the droplet transmission. 
Currently, our knowledge of the mysterious behaviors 
of SARS-CoV-2 in terms of transmission, diagnostics, 
prevention, and therapeutic strategies is increasing. In 
general, prevention seems to be the best way to reduce 
the transmission of the virus since no vaccine or 
effective treatment has yet been found. 
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